First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 shares of common stock on October 19, 2026. In connection with the closing, the company entered into a registration rights agreement requiring it to file a resale registration statement for the investors within 30 days.
First Tracks Biotherapeutics Capital Raise of $200M
First Tracks Biotherapeutics entered into a securities purchase agreement for a $200 million private placement (PIPE) of 6,106,870 shares of common stock at $32.75 per share. The offering includes participation from several institutional investors and is intended to fund the clinical development of ANB033 and other general corporate purposes.
Value
$200M
Counterparty
Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital